CSL Behring Medical Expert Portal is a European webpage designed for healthcare professionals (HCPs) who are interested in serious and life-threatening conditions. Register and login to access the information on this webpage and to receive updates when new content becomes available. If you are interested in the relevant content for a specific country, please refer to the CSL Behring affiliate in your country to obtain relevant information. The medical and scientific information provided on this website is for informational purposes only and should not replace professional advice from a healthcare provider in your area. It is important that you always adhere to the regulations and guidelines relevant to your country.

Disclaimer: Due to compliance regulations, not all content of this webpage is intended for UK healthcare practitioners. If you would like to access UK specific materials on this site, please reach out to your local CSL Behring medical representative (medinfo@cslbehring.com) for assistance.

Disclaimer

CSL EXPERT HIVE

Symposia replays

Advances in von Willebrand disease (VWD): A view from the clinic

Pathology:

Von Willebrand Disease

ISTH, 30th Annual Congress, July 9–13, 2022 

Watch the full video recording of the CSL Behring VWD Product Theatre held on July 11, 2022.

The meeting was chaired by Augusto Federici (Italy) and was followed by three presentations, given by himself, Susan Halimeh (Germany) and Carolyn Millar (UK). The presentations focused on specific patient cases, detailing various experiences in the treatment of VWD. The session finished with an interactive question and answer session with the faculty and audience, which was moderated by Susan Halimeh.

Please note that this product theatre contains information on specific products and indications. The Summary of Product Characteristics (SmPC) and/or local prescribing information provided may vary depending on local approval in each country. Haemate® P is not licensed for use in the UK. Voncento® is licensed for use in the UK. Best efforts were undertaken by CSL Behring and congress sponsors to ensure compliance with EFPIA Code of Practice in line with the Joint Guidelines (IFPMA, EFPIA and PhRMA). However, you should review your local prescribing information and/or SmPC and consult directly with the local affiliate of CSL Behring to address any questions.